Business Wire

PA-SYNERGIS-SOFTWARE

9.3.2022 15:24:09 CET | Business Wire | Press release

Share
Synergis Software Rebrands Adept Engineering Document Management with Increased Investments to Accelerate Growth

Synergis Software, a global leader in engineering document management and workflow solutions, today announced a rebrand and new website in synchrony with major investments in product development and customer success. These initiatives will fast track the company’s delivery of superior products and services to their global customer base.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220309005289/en/

“We see so much opportunity to have a positive impact on the customers we serve, which is why we’re making major investments in the company," states Scott Lamond, vice president of marketing at Synergis Software. "We want our brand to align with our mission of transforming the way our customers work— providing greater clarity, control, alignment, and harmony—so they can accelerate engineering projects, streamline operations, reduce risk, and lower costs." Watch the rebrand video .

The Adept platform is used by 120,000 users worldwide, including Dow Chemical, Con Edison, Amazon, Merck, and General Mills, and is managing over $1B in digital assets.

“Adept manages billions of dollars of digital assets containing priceless Dow intellectual property, with thousands of users across several dozen global sites," says Teresa Yang, Product Manager, Document Management, Dow Chemical.

Synergis is committed to accelerating the company’s growth and elevating the value delivered to customers with significant investments in their products.

“We’re tripling the size of our software development organization. By the end of 2022, our team will have grown by 218% in just two years,” explains Todd Cummings, vice president of research and development at Synergis. “The added positions include developers, QA staff, product managers, DevOps, SCRUM Masters, and User Experience professionals. Key leaderships roles are in place to help us refine the processes, tools, and methods we use to develop and deliver more value, faster.”

Synergis is investing substantially in the Adept platform, including the upcoming release of a new, integrated visualization solution for 2D and 3D engineering designs and other document types, along with major new feature enhancements and support for new versions of mainstream CAD systems. A new Cloud version of Adept is underway for customers who want to lower their IT costs and simplify deployment and upgrades.

“We’ll continue to build on Synergis Software’s legacy of extraordinary, love-based service and treating customers like family," adds Lamond. Toward that end, Synergis is expanding its customer success team, developing an online “Adept Academy”, and launching three new services options, including:

  • Ongoing Technical Consulting - Customers can work one-on-one with a dedicated Adept technical consultant on a regular basis to improve their Adept environment, streamline processes, remove roadblocks, and increase the value of Adept to their organization. Synergis experts will provide strategic and technical guidance on nearly any type of project to help customers reach their goals.
  • Remote Adept Administration - Customers can outsource the day-to-day application management and administration of Adept to our experienced technical staff to keep their resources focused on what’s most important to their business. Our managed services will help keep our customer’s Adept environment optimized and lower operating costs.
  • Adept Server Hosting - Customers can outsource the hosting of their entire Adept Server environment to free up IT resources, lower operating costs, and improve security.

Synergis Software’s focus and investments in service and support will help maintain their strong leadership position in the market, as validated in the rankings on the G2 software review site.

“We couldn’t have arrived at this moment without 30 years of thoughtful, collaborative, and visionary support from our customer community and the individuals who have shaped us,” added Lamond. “We’re grateful for their influence as we build our future together.”

About Synergis Software

Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects enterprise applications so critical data and business processes can flow seamlessly across the entire IT infrastructure.

Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, the company's commitment to its customers is unwavering.

Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded. For more information, visit SynergisSoftware.com.

Link:

ClickThru

Social Media:

https://www.facebook.com/synergissoftware/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye